Originally Aired: October 12, 2022
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Alzheimer’s disease (AD) is the most common form of neurodegenerative disease, estimated to contribute to 60–70% of all cases of dementia worldwide. Increasing evidence suggests that neuroinflammation, primarily mediated by microglia, contributes to the onset and progression of AD. Hence, microglia are considered a major therapeutic target that could potentially yield effective disease-modifying treatments for AD. However, despite the interest in studying microglia as AD drug targets, the lack of accurate, consistent, and scalable microglial cellular models hinders drug discovery and development.

In this GEN webinar, join our distinguished expert, Dr. Matthias Pawlowski, to learn about the emerging role of microglia in the pathogenesis of AD and their potential as a therapeutic target to treat this disease effectively. Additionally, Dr. Malathi Raman will present data on the validation of bit.bio’s hiPSC-derived ioMicroglia cells as a potential human-based cellular model for AD research and drug development, including the expression of specific markers (TMEM119, P2RY12, IBA1), key phagocytic & cytokine secretion functions, and co-culture compatibility with glutamatergic neurons.


A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.

 

Webinar produced with support from:

bit.bio logo

 

Matthias Pawlowski
Matthias Pawlowski, MD, PhD
Head, Dementia-Sensitive Hospital
University Hospital Münster, Germany
Malathi Raman
Malathi Raman, PhD
Senior Product Manager
bit.bio